Skip to main content
Fig. 3 | BMC Gastroenterology

Fig. 3

From: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

Fig. 3

Sustained virologic response in patients with HCV genotype 1 and 3 infections. SVR12 (mITT analysis) rates by HCV subgenotype are shown according to baseline cirrhosis status and prior HCV therapy in patients with HCV genotype 1 a and 3 b infection patients. Error bars indicate 95% confidence intervals

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us